---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-009495"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2026-02-03T23:59:59+00:00"
generated_at: "2026-05-16T05:27:08.860094+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merck Q4 Non-GAAP EPS $2.04 (+19% YoY); FY2026 guidance $5.00-$5.15 on Cidara charge

## Summary
- Q4 2025 sales $16.4B (+5% GAAP EPS $1.19, Non-GAAP EPS $2.04).
- Full-year sales $65.0B; Non-GAAP EPS $8.98 (+17% YoY).
- KEYTRUDA $31.7B (+7%); WINREVAIR $1.4B; GARDASIL $5.2B (-39% on China weakness).
- FY2026 sales guidance $65.5-$67.0B; Non-GAAP EPS $5.00-$5.15 includes ~$3.65 Cidara charge.
- Acquired Verona Pharma and Cidara; 18 positive Phase 3 trials in 2025.

## SEC filing metadata
- accession: 0001104659-26-009495
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2026-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/0001104659-26-009495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-009495
- JSON: https://secwatch.observer/filing/0001104659-26-009495.json
- Plain text: https://secwatch.observer/filing/0001104659-26-009495.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.